Sulfaguanidine

Summary

Sulfaguanidine (CHEMBL338802) is an approved small-molecule antiinfective agent (ATC A07AB03).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A07AB03
• Chemistry: 214.25 Da · C7H10N4O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL338802
Name	Sulfaguanidine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5324
ChEBI	CHEBI:94621
ATC	A07AB03
Molecular formula	C7H10N4O2S
Molecular weight	214.25
InChIKey	BRBKOPJOKNSWSG-UHFFFAOYSA-N

SMILES: C1=CC(=CC=C1N)S(=O)(=O)N=C(N)N

IUPAC name: 2-(4-aminophenyl)sulfonylguanidine

ChEBI definition: A sulfonamide incorporating a guanidine moiety used to block the synthesis of folic acid; mostly used in veterinary medicine

Pharmacological roles (ChEBI): antiinfective agent.

Also known as: Gppe susp fte, Guanimycin, NSC-14041, Sulfaguanidina, Sulfaguanidine, sulphaguanidine, SID11112136, SID856017, SULFAGUANIDINE, SID144203880, SID170465708, sulfaguanidine

Patent coverage: 1,769 distinct patent families (4,956 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,848 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Prelamin-A/C, Beta-lactamase, Prothrombin, Trypsin, Protein argonaute-2.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	7.75	Potency	17.8	nM	CHEMBL_ACT_3625546
F2	7.02	Ki	95	nM	CHEMBL_ACT_820907
PRSS1	5.87	Ki	1350	nM	CHEMBL_ACT_820908
P00811	5.2	Potency	6310	nM	CHEMBL_ACT_4636527

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).